Roche Holding AG / Anadys Pharmaceuticals, Inc.

Chronic Hepatitis C Virus Infection

67K US cases/yr

Disease Overview

Chronic hepatitis C is a liver infection caused by the HCV virus that, untreated, leads to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. At the time of the 2011 deal, standard of care was 24-48 weeks of pegylated interferon plus ribavirin with cure rates of ~40-50% in genotype 1 patients and significant tolerability burden, driving an industry race for interferon-free direct-acting antiviral regimens.

Competitive Landscape

In late 2011, the HCV market was undergoing rapid transformation. Vertex's Incivek (telaprevir) and Merck's Victrelis (boceprevir) — first-generation NS3/4A protease inhibitors — had just launched in mid-2011, both still requiring interferon/ribavirin backbones. The strategic prize was an all-oral, interferon-free regimen, and competitors were assembling DAA toolkits: Gilead acquired Pharmasset for $11B in November 2011 for sofosbuvir (NS5B nucleotide), BMS acquired Inhibitex for $2.5B in January 2012 for INX-189, and Vertex was advancing VX-222 (a non-nuke NS5B). Roche's existing HCV franchise (Pegasys/Copegus, generating ~CHF 1.05B in 9M 2011) was the legacy interferon backbone vulnerable to disruption. The Anadys deal added setrobuvir (ANA598), a non-nucleoside NS5B polymerase inhibitor in Phase 2b, plus ANA773, a TLR7 agonist — giving Roche complementary mechanisms to combine with its protease inhibitor danoprevir and nucleoside RG7128 (mericitabine). Roche ultimately discontinued setrobuvir in July 2015 after Gilead's sofosbuvir/Sovaldi (2013) and Harvoni (2014) reset the standard of care. (Source: https://en.wikipedia.org/wiki/Setrobuvir)